Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Etoricoxib sustained release tablet and preparation method thereof

A technology of etoricoxib and sustained-release tablets, which is applied in the field of pharmaceutical preparations and its preparation, can solve the problems of unseen glycerol monostearate, etc., and achieve the effects of expanded production, good sustained-release effect, and simple process

Inactive Publication Date: 2018-05-04
佛山市弘泰药物研发有限公司
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the matrix materials of sustained-release tablets, there are no reports on glyceryl monostearate and glyceryl palmitate stearate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1: Preparation of etoricoxib sustained-release tablets

[0034] Take by weighing 2.5g etoricoxib, 2.5g glyceryl palmitate stearate, 5g microcrystalline cellulose, cross 80 mesh sieves after mixing uniformly according to the equal volume addition method, the waxy molten liquid of 2.5g (0.5g white beeswax, 1g of palm wax and 1g of PEG6000 plus ethanol (melted at 85°C and then dried to remove ethanol) were added to the mixture of the main drug, microcrystalline cellulose and glyceryl palmitate stearate, and the ethanol solution of PVPK30 (concentration: 5%wt.) was used as Binder (solution dosage: 10g) made of soft material, granulated with a 30-mesh sieve, dried at 60°C for 1 hour, granulated with a 30-mesh sieve, added with 0.2g of magnesium stearate and 0.3g of silicon dioxide, mixed evenly, and pressed into tablets.

Embodiment 2

[0035] Embodiment 2: Preparation of etoricoxib sustained-release tablets

[0036] Take by weighing 2.5g etoricoxib, 5g glyceryl palmitate stearate, 2.5g microcrystalline cellulose, cross 80 mesh sieves after mixing uniformly according to the equivalent incremental method, 2.5g waxy molten liquid (0.5g white beeswax, 1g of palm wax and 1g of PEG6000 plus ethanol (melted at 85°C and then dried to remove ethanol) were added to the mixture of the main drug, microcrystalline cellulose and glyceryl palmitate stearate, and the ethanol solution of PVPK30 (concentration: 5%wt.) was used as Binder (solution dosage: 10g) made of soft material, granulated with a 30-mesh sieve, dried at 60°C for 1 hour, granulated with a 30-mesh sieve, added with 0.2g of magnesium stearate and 0.3g of silicon dioxide, mixed evenly, and pressed into tablets.

Embodiment 3

[0037] Embodiment 3: Preparation of etoricoxib sustained-release tablets

[0038]Weigh 3.5g etoricoxib, 0.5g glyceryl monostearate, and 2.5g microcrystalline cellulose, mix them evenly according to the equal-volume incremental method and pass through an 80-mesh sieve, and 2g of waxy molten liquid (1.5g white beeswax and 0.5 gPEG2000 plus ethanol was melted at 85°C and then dried to remove ethanol) was added to the mixture of the main drug, microcrystalline cellulose and glyceryl stearate, and the ethanol solution of PVPK30 (concentration: 2%wt.) was used as a binder ( The amount of solution is 10g) to make soft material, granulate with 30 mesh sieve, dry at 60°C for 1 hour, after granulation with 30 mesh sieve, add 0.1g magnesium stearate, mix well, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicinal preparations, and discloses an Etoricoxib sustained release tablet and a preparation method thereof. The sustained release tablet disclosed by the invention comprises the following components in percentages by weight: 10% to 40% of Etoricoxib, 50% to 80% of a hydrophobic framework material, 1% to 5% of an adhesive and 0.5% to 5% of a lubricating agent, wherein the hydrophobic framework material is a mixture of microcrystalline cellulose, glyceride, wax and a fusogenic agent; the glyceride is one or two of glycerin monostearate and glyceryl palmitostearate; the wax is one or two of cera alba and palm wax. The sustained release tablet disclosed by the invention comprises a hydrophobic framework material and the like, the release of medicine canbe regulated and controlled preferably, and the technology is simple and is beneficial for expanded production.

Description

technical field [0001] The invention relates to a pharmaceutical preparation and a preparation method thereof, in particular to an etoricoxib sustained-release tablet and a preparation method thereof. Background technique [0002] Etoricoxib (trade name: Ankangxin®), a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic effects, was approved in Europe on June 24, 2011, for Treatment of osteoarthritis (OA), rheumatoid arthritis and acute gouty arthritis. Developed and produced by Merck (known as Merck in the United States and Canada), it is currently on the market in 84 countries and regions around the world, including China. Other indications currently approved in Mexico, Brazil and Peru include: relief of post-extraction pain and primary dysmenorrhea, relief of chronic musculoskeletal pain, including chronic back pain, etc. It is also clinically used in the treatment of primary menstrual pain, ankylosing spondylitis, pain after dental surger...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/22A61K31/444A61K47/38A61K47/14A61K47/44A61P29/00
CPCA61K31/444A61K9/2013A61K9/2054
Inventor 雷林芳
Owner 佛山市弘泰药物研发有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com